Edoxaban/Selected P-glycoprotein (P-gp) Inducers Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may lower the amount of edoxaban in your blood.
What might happen:
Your edoxaban may not work as well and your risk of an unwanted blood clot may increase.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor and pharmacist) know that you are taking these medicines together, if you have started taking apalutamide, carbamazepine, fosphenytoin, lorlatinib, phenytoin, or St. John's wort in the previous week, or if you stopped taking apalutamide, carbamazepine, efavirenz, fosphenytoin, lorlatinib, phenytoin, rifapentine, or St. John's wort in the past two weeks. Your doctor may want to change or adjust the dose of your edoxaban.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Lixiana (edoxaban tosilate) UK summary of product characteristics. Daiichi Sankyo UK Limited July 2, 2015.
- 2.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 3.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 4.Savaysa (edoxaban) US prescribing information. Daiichi Sankyo, Inc August, 2019.
- 5.FDA Center for Drug Evaluation and Research (CDER). Application number 206316 Savaysa (edoxaban tosylate) Clinical Pharmacology and Biopharmaceutics Review. available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s00 0ClinPharmR.pdf January 8, 2015.
- 6.Lanier C, Fuller M, Reece BA. Novel Drug-Drug Interaction of Potential Rifabutin-Induced Edoxaban Failure: A Case Report. J Pharm Pract 2023 Nov 6;8971900231213702.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.